Journal article
F44. AN ADD-ON TRIAL WITH N-ACETYL-CYSTEINE (NAC) IN EARLY PSYCHOSIS PATIENTS: TOWARDS BIOMARKER GUIDED TREATMENT
Philippe Conus, Margot Fournier, Lijing Xin, Martine Cleusix, Philipp S Baumann, Carina Ferrari, Ann Cousins, Luis Alameda, Mehdi Gholam-Razaee, Philippe Golay, Raoul Jenni, Tsung-Ung Wilson Woo, Matcheri Keshavan, Chin B Eap, Joanne Wojcik, Michel Cuenod, Thierry Buclin, Rolf Gruetter, Larry Seidman, Kim Do
Schizophrenia bulletin | Published : 2018
Abstract
Abstract Background Oxidative stress, coupled with dysregulation of inflammation, NMDAR and dopamine, is involved in schizophrenia (SZ) pathophysiology. Earlier add-on clinical trials showed in chronic SZ patients that NAC, a precursor of glutathione (GSH), an important cerebral antioxidant, improved negative symptoms, mismatch negativity and local synchronization. We hypothesized that NAC at an earlier stage of illness would have a greater impact. Methods Early psychosis patients (EP, less than 5 years of illness, N=63; NAC=32, placebo=31) were supplemented with NAC (2.7g/day, 6 months) in a double-blind randomized placebo-controlled trial. Outcome measures: PANSS and neurocognition (MATRIC..
View full abstract